Business

Bausch + Lomb Advancing Two First-in-Class Eye Health Therapies Based on Trial Results

Financial Post · August 24, 2026 at 4:35 p.m.

VAUGHAN, Ontario -- Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that two of its pharmaceutical pipeline assets – both first-in-class treatments – will advance to new trials based on recent clinical results.

Read the full article on Financial Post ›

5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on financialpost.com — the content belongs to Financial Post.

Bausch + Lomb Advancing Two First-in-Class Eye Health Therapies Based on Trial Results

More from Financial Post

Snow Alert: It’s Snowing in Ikon Pass Country

William Watson: Let’s see the last draft. Inquiring voters want to know

Opinion: We need to reduce wildfire fuel and zone better

Zacatecas Silver Closes the Second Tranche of Non-Brokered Private Placement

More in Business

Snow Alert: It’s Snowing in Ikon Pass Country

Old soup factory takes on new high-tech life as quantum computing firm gets $195M federal boost

William Watson: Let’s see the last draft. Inquiring voters want to know

Opinion: We need to reduce wildfire fuel and zone better

Zacatecas Silver Closes the Second Tranche of Non-Brokered Private Placement

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera